Question:
A 63-year-old woman presented with left-sided abdominal pain and hematochezia noted over a week prior to hospitalization. She had been using antihypertensive medicine and did not report any other significant medical difficulties. A screening colonoscopic examination performed a year prior to presentation had been unremarkable. Abdominal CT showed segmental wall thickening with decreased enhancement of the proximal descending colon in addition to pericolic fat infiltration (Fig. A) . Colonoscopic examination performed at Chungnam National University Hospital showed diffuse erythematous friable ulcerations located approximately 35 to 30 cm above the anal verge, and a biopsy was performed (Fig. B) . Laboratory studies did not Gastrointestinal (GI) involvement is usually secondary to the reactivation of latent infection in immunosuppressed patients. For example, patients who are treated with organor bone marrow-transplantation or are diagnosed with acquired immune deficiency syndrome, or those who use medicines such as immunosuppressants (anti-tumor necrosis factor antibodies, steroids) or chemotherapeutic agents. However, GI involvement is uncommon in immunocompetent patients. The cytomegalovirus (CMV) causes a variety of diseases in the lower GI tract such as colitis, ileitis, appendicitis, and colonic obstruction. [1] [2] [3] The common presenting symptoms of CMV colitis are diarrhea, fever, abdominal pain, and approximately 50% of the patients demonstrate hematochezia. 4 In a retrospective study comprising immunocompetent patients diagnosed with CMV colitis, the most common endoscopic findings were: well-demarcated ulcerations (50%), ulceroinfiltrative changes (25%), and pseudomembrane formation (25%). 5 It is necessary to differentiate between CMV and ischemic colitis when an elderly patient presents with bloody diarrhea and abdominal pain.
Currently, the drugs available for treatment of CMV infection include ganciclovir, valganciclovir, foscarnet, and cidofovir. In immunocompetent patients diagnosed with CMV infection, ganciclovir is the most preferred antiviral drug. After a definitive diagnosis of CMV colitis, our patient was treated with intravenous administration of ganciclovir at a dose of 200 mg per 12 hours for 2 weeks. A follow-up colonoscopic examination showed improvement in the colonic ulcers (Fig. G) and disappearance of the CMV inclusion bodies and CMV-positive cells.
CMV enteritis in immunocompetent patients may occur in elderly patients or in those with a concomitant underlying disease. CMV colitis results in poor outcomes without the administration of antiviral treatment. Antiviral therapy is recommended for the management of immunocompetent patients. The prognosis is relatively good if the condition is promptly and correctly diagnosed and treated.
